Market Research Logo

Peripheral Neuropathic Pain - Pipeline Review, H2 2016

Peripheral Neuropathic Pain - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides an overview of the Peripheral Neuropathic Pain (Central Nervous System) pipeline landscape.

Peripheral neuropathic pain is a chronic pain state that usually is accompanied by tissue injury. Causes include alcoholism, diabetes, chemotherapy, infections, surgery and multiple sclerosis. Symptoms include burning pain, tingling and numbness. Treatment includes non-steroidal anti-inflammatory drugs, anticonvulsant and antidepressant drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Neuropathic Pain - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Neuropathic Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 5, 8 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Peripheral Neuropathic Pain.

Peripheral Neuropathic Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Neuropathic Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Neuropathic Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Neuropathic Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Peripheral Neuropathic Pain Overview
Therapeutics Development
Pipeline Products for Peripheral Neuropathic Pain - Overview
Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis
Peripheral Neuropathic Pain - Therapeutics under Development by Companies
Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
Peripheral Neuropathic Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Peripheral Neuropathic Pain - Products under Development by Companies
Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes
Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development
Achelios Therapeutics, Inc.
AnaBios Corporation
Chromocell Corporation
GW Pharmaceuticals Plc
Nektar Therapeutics
Phosphagenics Limited
Spherium Biomed S.L.
Sunovion Pharmaceuticals Inc.
Yuhan Corporation
Zynerba Pharmaceuticals, Inc.
Peripheral Neuropathic Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AXPN-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-8464 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DSP-2230 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nabiximols - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NKTR-171 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxycodone ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sepiapterin Reductase for Neuropathic and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SP-15001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peripheral Neuropathic Pain - Dormant Projects
Peripheral Neuropathic Pain - Discontinued Products
Peripheral Neuropathic Pain - Product Development Milestones
Featured News & Press Releases
Oct 12, 2016: FDA Fast Track Designation and First Subject Dosing with Lead Candidate CC8464/ASP1807 for the Management of Neuropathic Pain Associated with iSFN
Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Peripheral Neuropathic Pain, H2 2016
Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H2 2016
Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2016
Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H2 2016
Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2016
Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2016
Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2016
Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H2 2016
Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
Peripheral Neuropathic Pain - Pipeline by Yuhan Corporation, H2 2016
Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Peripheral Neuropathic Pain - Dormant Projects, H2 2016
Peripheral Neuropathic Pain - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Peripheral Neuropathic Pain, H2 2016
Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report